N6-Cyclohexyladenosine

N6-Cyclohexyladenosine is a selective adenosine A1 receptor agonist (EC₅₀ = 8.2 nM). N6-Cyclohexyladenosine enhances the activation of the PI3K/Akt/CREB/BDNF axis. N6-Cyclohexyladenosine promotes remyelination, induces sleep, and improves 3-NP-induced Huntington's disease. N6-Cyclohexyladenosine can be used in liver cancer research^{[1][2][3][4][5][6][7]}. In Vitro: N6-Cyclohexyladenosine reduces the extent of demyelination and promote remyelination in rat optic chiasm^[1].
N6-Cyclohexyladenosine (10 nM-50 μM; 20 h) significantly increases the secretion of Erythropoietin in human hepatoma cell line Hep 3B under hypoxic conditions^[4].
In Vivo: N6-Cyclohexyladenosine (2 μL, 1%; injected inside the right lateral ventricle; administered daily during the demyelination phase (days 0-13) or the remyelination phase (days 14-27)) in a rat optic chiasm demyelination model can reduce the extent of demyelination, promote remyelination, and improve visual evoked potential-related indicators^[1].
N6-Cyclohexyladenosine (10-100 μM; infused into the basal forebrain via a microdialysis probe) can induce sleep in a rat model of basal forebrain cholinergic neuron injury ^[2].
N6-Cyclohexyladenosine (60 μg/kg; i.p.) is a potent locomotor depressant in mice^[3].
N6-Cyclohexyladenosine (6.25 nM/1 μL; intrastriatal injection; single) attenuates neuronal death and improves cognitive and motor deficits in a rat model of Huntington's disease induced by 3-NP^[6].
N6-Cyclohexyladenosine (1.5 mg/kg induction dose, followed by three 1.0 mg/kg doses every 6 hours for a total of 4 doses; i.p.; 4 times) does not show neuroprotective effects in a rat model of middle cerebral artery occlusion (MCAO), failing to reduce infarct volume and improve neurological function^[7].